Cargando…
Assessing intestinal permeability in Crohn’s disease patients using orally administered (52)Cr-EDTA
BACKGROUND: Intestinal permeability can be assessed by monitoring renal excretion of orally administered radioactively (51)Cr-labeled ethylenediaminetetraacetic acid ((51)Cr-EDTA). Although considered safe, patient participation in using radio-labeled tracers is low. Here, we used orally administere...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366711/ https://www.ncbi.nlm.nih.gov/pubmed/30730969 http://dx.doi.org/10.1371/journal.pone.0211973 |
_version_ | 1783393649035313152 |
---|---|
author | von Martels, Julius Z. H. Bourgonje, Arno R. Harmsen, Hermie J. M. Faber, Klaas Nico Dijkstra, Gerard |
author_facet | von Martels, Julius Z. H. Bourgonje, Arno R. Harmsen, Hermie J. M. Faber, Klaas Nico Dijkstra, Gerard |
author_sort | von Martels, Julius Z. H. |
collection | PubMed |
description | BACKGROUND: Intestinal permeability can be assessed by monitoring renal excretion of orally administered radioactively (51)Cr-labeled ethylenediaminetetraacetic acid ((51)Cr-EDTA). Although considered safe, patient participation in using radio-labeled tracers is low. Here, we used orally administered (52)Cr-EDTA as non-radioactive alternative to assess intestinal permeability in CD and analyzed the association with disease activity, disease location and gut microbial dysbiosis. MATERIALS AND METHODS: 60 CD patients with low (n = 25) and increased (n = 35) fecal calprotectin levels (cut-off: 100 μg/g feces) ingested 20 mL (52)Cr-EDTA (20 mmol/L) solution whereafter 24-h urine was collected. Urinary (52)Cr-EDTA concentrations were quantified using Inductively Coupled Plasma Mass Spectrometry (ICP-MS). Fecal Enterobacteriaceae and Faecalibacterium prausnitzii were quantified using FISH. Correlations between urinary (52)Cr-EDTA excretion and other parameters were established using nonparametric Spearman’s correlation coefficients (ρ). RESULTS: CD patients with increased fecal calprotectin levels (> 100 μg/g) demonstrated an elevated urinary (52)Cr-EDTA/creatinine ratio (772 vs. 636 μmol/mol, P = 0.132). Patients with primarily colonic disease showed the highest (52)Cr-EDTA excretion. Importantly, a positive correlation was observed for the urinary (52)Cr-EDTA/creatinine ratio and fecal calprotectin levels (ρ = 0.325, P < 0.05). Finally, urinary (52)Cr-EDTA/creatinine ratio negatively correlated with the relative abundance of Faecalibacterium prausnitzii (ρ = -0.221, P = 0.092), while positively correlating with Enterobacteriaceae (ρ = 0.202, P = 0.126). CONCLUSIONS: Orally administered and renal excreted (52)Cr-EDTA may be used to assess intestinal permeability in CD and correlates with fecal calprotectin levels and bacterial species relevant to CD. This test may improve non-invasive detection of disease exacerbations and help monitor disease activity. |
format | Online Article Text |
id | pubmed-6366711 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-63667112019-02-22 Assessing intestinal permeability in Crohn’s disease patients using orally administered (52)Cr-EDTA von Martels, Julius Z. H. Bourgonje, Arno R. Harmsen, Hermie J. M. Faber, Klaas Nico Dijkstra, Gerard PLoS One Research Article BACKGROUND: Intestinal permeability can be assessed by monitoring renal excretion of orally administered radioactively (51)Cr-labeled ethylenediaminetetraacetic acid ((51)Cr-EDTA). Although considered safe, patient participation in using radio-labeled tracers is low. Here, we used orally administered (52)Cr-EDTA as non-radioactive alternative to assess intestinal permeability in CD and analyzed the association with disease activity, disease location and gut microbial dysbiosis. MATERIALS AND METHODS: 60 CD patients with low (n = 25) and increased (n = 35) fecal calprotectin levels (cut-off: 100 μg/g feces) ingested 20 mL (52)Cr-EDTA (20 mmol/L) solution whereafter 24-h urine was collected. Urinary (52)Cr-EDTA concentrations were quantified using Inductively Coupled Plasma Mass Spectrometry (ICP-MS). Fecal Enterobacteriaceae and Faecalibacterium prausnitzii were quantified using FISH. Correlations between urinary (52)Cr-EDTA excretion and other parameters were established using nonparametric Spearman’s correlation coefficients (ρ). RESULTS: CD patients with increased fecal calprotectin levels (> 100 μg/g) demonstrated an elevated urinary (52)Cr-EDTA/creatinine ratio (772 vs. 636 μmol/mol, P = 0.132). Patients with primarily colonic disease showed the highest (52)Cr-EDTA excretion. Importantly, a positive correlation was observed for the urinary (52)Cr-EDTA/creatinine ratio and fecal calprotectin levels (ρ = 0.325, P < 0.05). Finally, urinary (52)Cr-EDTA/creatinine ratio negatively correlated with the relative abundance of Faecalibacterium prausnitzii (ρ = -0.221, P = 0.092), while positively correlating with Enterobacteriaceae (ρ = 0.202, P = 0.126). CONCLUSIONS: Orally administered and renal excreted (52)Cr-EDTA may be used to assess intestinal permeability in CD and correlates with fecal calprotectin levels and bacterial species relevant to CD. This test may improve non-invasive detection of disease exacerbations and help monitor disease activity. Public Library of Science 2019-02-07 /pmc/articles/PMC6366711/ /pubmed/30730969 http://dx.doi.org/10.1371/journal.pone.0211973 Text en © 2019 von Martels et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article von Martels, Julius Z. H. Bourgonje, Arno R. Harmsen, Hermie J. M. Faber, Klaas Nico Dijkstra, Gerard Assessing intestinal permeability in Crohn’s disease patients using orally administered (52)Cr-EDTA |
title | Assessing intestinal permeability in Crohn’s disease patients using orally administered (52)Cr-EDTA |
title_full | Assessing intestinal permeability in Crohn’s disease patients using orally administered (52)Cr-EDTA |
title_fullStr | Assessing intestinal permeability in Crohn’s disease patients using orally administered (52)Cr-EDTA |
title_full_unstemmed | Assessing intestinal permeability in Crohn’s disease patients using orally administered (52)Cr-EDTA |
title_short | Assessing intestinal permeability in Crohn’s disease patients using orally administered (52)Cr-EDTA |
title_sort | assessing intestinal permeability in crohn’s disease patients using orally administered (52)cr-edta |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366711/ https://www.ncbi.nlm.nih.gov/pubmed/30730969 http://dx.doi.org/10.1371/journal.pone.0211973 |
work_keys_str_mv | AT vonmartelsjuliuszh assessingintestinalpermeabilityincrohnsdiseasepatientsusingorallyadministered52credta AT bourgonjearnor assessingintestinalpermeabilityincrohnsdiseasepatientsusingorallyadministered52credta AT harmsenhermiejm assessingintestinalpermeabilityincrohnsdiseasepatientsusingorallyadministered52credta AT faberklaasnico assessingintestinalpermeabilityincrohnsdiseasepatientsusingorallyadministered52credta AT dijkstragerard assessingintestinalpermeabilityincrohnsdiseasepatientsusingorallyadministered52credta |